The estimated Net Worth of Pedro Santabarbara is at least $184 dollars as of 4 September 2012. Pedro Santabarbara owns over 9,200 units of Infinity Pharmaceuticals stock worth over $184 and over the last 13 years Pedro sold INFI stock worth over $0.
Pedro has made over 1 trades of the Infinity Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently Pedro exercised 9,200 units of INFI stock worth $59,800 on 4 September 2012.
The largest trade Pedro's ever made was exercising 9,200 units of Infinity Pharmaceuticals stock on 4 September 2012 worth over $59,800. On average, Pedro trades about 2,300 units every 0 days since 2012. As of 4 September 2012 Pedro still owns at least 9,200 units of Infinity Pharmaceuticals stock.
You can see the complete history of Pedro Santabarbara stock trades at the bottom of the page.
Pedro's mailing address filed with the SEC is C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over $485,846,497 worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth $175,155,554 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... et Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $14,976. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth $15,363.
the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business
Infinity Pharmaceuticals executives and other stock owners filed with the SEC include: